This antibody reacts with an epitope at aa 469-592 (exon 7/8). It primarily reacts with human, but also reacts very weakly with cow, pig and sheep.
This antibody can inhibit insulin binding (~80%). It can also be used in a Tyrosine Kinase assay (Ab-mediated capture on microtitre plates).
Without BSA, this antibody can be used as an insulin-like agonist. Without BSA, it can also be used as both a capture and detection antibody in a sandwich ELISA.
Biological actions of insulin and IGF-1 are mediated by their respective cell surface receptor tyrosine kinases that regulate multiple signaling pathways through activation of a series of phosphorylation cascades. The insulin receptor. Insulin/IGF-1 binding to the extracellular domain leads to autophosphorylation of downstream target proteins. These two receptors differ in sequence in regions that confer specificity for the designated ligand as well as in certain intracellular signaling domains, resulting in significant differences in the functional consequences of activation of each receptor. Defects in IR are the cause of various insulin resistance syndromes and IGF-1R defects may cause some forms of growth retardation. Both these signaling cascades are also important for the development of cancer.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: CD220; CD220 beta; Insulin receptor; Insulin receptor subunit alpha; Insulin receptor subunit beta; IR; IR alpha; IR beta
Gene Aliases: CD220; HHF5; INSR; ir; ir-A
UniProt ID: (Human) P06213
Molecular Function: transmembrane signal receptor